ロード中...
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ malignancies. However, the etiological nature of neurologic complications remains a conundrum. In our study, the evidence of blood-brain barrier (BBB)-penetrating CAR T cells as a cu...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4986179/ https://ncbi.nlm.nih.gov/pubmed/27526682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0299-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|